HC Wainwright Reiterates “Buy” Rating for Zevra Therapeutics (NASDAQ:ZVRA)

HC Wainwright reaffirmed their buy rating on shares of Zevra Therapeutics (NASDAQ:ZVRA) in a research report released on Thursday,Benzinga reports. HC Wainwright currently has a $20.00 price objective on the stock.

Other equities analysts have also recently issued research reports about the company. Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a report on Wednesday. Guggenheim set a $21.00 price target on Zevra Therapeutics and gave the company a “buy” rating in a research report on Tuesday, February 4th. Canaccord Genuity Group lowered their price target on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $25.00 price objective on shares of Zevra Therapeutics in a report on Wednesday. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Zevra Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $22.14.

Zevra Therapeutics Trading Up 0.3 %

NASDAQ:ZVRA opened at $7.94 on Thursday. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics has a twelve month low of $4.20 and a twelve month high of $9.76. The company has a market cap of $423.81 million, a P/E ratio of -4.03 and a beta of 1.98. The business has a 50 day moving average price of $7.93 and a two-hundred day moving average price of $8.14.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its earnings results on Tuesday, March 11th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.28). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The business had revenue of $12.00 million for the quarter, compared to analyst estimates of $8.93 million. As a group, analysts expect that Zevra Therapeutics will post -1.95 EPS for the current fiscal year.

Insider Activity

In other news, CEO Neil F. Mcfarlane sold 61,273 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $481,605.78. Following the transaction, the chief executive officer now directly owns 222,060 shares of the company’s stock, valued at $1,745,391.60. This represents a 21.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO R. Laduane Clifton sold 11,000 shares of Zevra Therapeutics stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $86,460.00. Following the sale, the chief financial officer now directly owns 51,361 shares of the company’s stock, valued at $403,697.46. The trade was a 17.64 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 85,773 shares of company stock valued at $674,176 over the last three months. Insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Zevra Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Woodline Partners LP lifted its holdings in Zevra Therapeutics by 2.2% during the 4th quarter. Woodline Partners LP now owns 4,139,593 shares of the company’s stock worth $34,524,000 after purchasing an additional 90,940 shares during the last quarter. Velan Capital Investment Management LP grew its stake in shares of Zevra Therapeutics by 50.0% in the fourth quarter. Velan Capital Investment Management LP now owns 300,000 shares of the company’s stock valued at $2,502,000 after acquiring an additional 100,000 shares in the last quarter. Squarepoint Ops LLC boosted its holdings in Zevra Therapeutics by 36.1% in the 4th quarter. Squarepoint Ops LLC now owns 16,534 shares of the company’s stock valued at $138,000 after purchasing an additional 4,384 shares during the period. ProShare Advisors LLC bought a new stake in shares of Zevra Therapeutics in the fourth quarter valued at approximately $145,000. Finally, Millennium Management LLC boosted its stake in shares of Zevra Therapeutics by 138.2% in the fourth quarter. Millennium Management LLC now owns 233,132 shares of the company’s stock valued at $1,944,000 after buying an additional 135,246 shares during the period. Institutional investors and hedge funds own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.